Navigation Links
Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
Date:11/24/2009

ain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Arena's lorcaserin program and other of its research and development programs; results of clinical trials or preclinical studies may not be predictive of future results; clinical trials and studies may not proceed at the time or in the manner Arena expects or at all; Arena's ability to partner or commercialize lorcaserin or other of its compounds or programs; the timing and ability of Arena to receive regulatory approval for its drug candidates; Arena's ability to obtain additional funds; Arena's ability to obtain and defend its patents; and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.


Contact: Arena Pharmaceuticals, Inc.
Jack Lief
President and CEO

Cindy McGee
Manager, IR and Corporate Communications
858.453.7200, ext. 1479

Media Contact: Russo Partners
David Schull, President
'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... July 03, 2015 , ... Cuvettes have been used in countless labs for decades. ... find the cuvette they needed. As expected, this was a daunting and tiring process ... part because they were not able to navigate the complex catalog structure. , Now thanks ...
(Date:7/2/2015)... ... July 02, 2015 , ... Sleepless nights will become ... quality of sleep, launched its Indiegogo campaign on June 23. Sound sleepers and the ... technology makes it effortless to use, while the integration of the Bluetooth speaker, alarm ...
(Date:7/1/2015)... Mass. , July 1, 2015   ... most frequently cited advantages of Otezla are its ... safety profile, as reported by surveyed rheumatologists. Otezla ... launched for the treatment of active psoriatic arthritis ... The current standard of care includes conventional oral ...
(Date:7/1/2015)... , July 1, 2015  Axovant Sciences Ltd. ... on the treatment of dementia, today announced that ... July 22 at 5:45 p.m. EDT following its ... Association International Conference 2015 (AAIC). ... , Dr. Lawrence Friedhoff , Chief ...
Breaking Biology Technology:New Cuvette E-Commerce Website Launched by FireflySci 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3
... James Doyle was joined by University of Wisconsin Chancellor ... in pledging their full support for the continued growth ... ,The Governor, addressing a special meeting of the Wisconsin ... of stem cell research. I will veto any legislation ...
... Claire, WI - Getting a tiny magnetic head to ride ... a spinning hard drive is hard enough. But, try to ... to work against your bottom line. , ,This is ... manufacturer of suspension assemblies for nearly three quarters of the ...
... and some fail at starting new businesses. As they begin ... needs their new product or service, certain personality characteristics begin ... in the writing of their business plan that these personality ... business plan is a road map for the founders of ...
Cached Biology Technology:Governor Doyle Pledges Support for Stem Cell Research and Biotechnology Advancements 2Eau Claire Manufacturer Drives Your PC 2Eau Claire Manufacturer Drives Your PC 3Entrepreneurs and Business Plans 2
(Date:6/23/2015)...   Valencell, a leader in performance ... recent study that illustrates its PerformTek biometric technology ... In a study conducted at Valencell,s Biometric Lab, ... Apple Watch against a chest strap – the ... The study demonstrated that Valencell,s biometric technology delivers ...
(Date:6/17/2015)... , Deutschland und GERMANTOWN, Maryland , ... ®   Produktlinie mit DNA-Tests verbessert ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... neue STR-Testkits der Produktlinie Investigator ® ... den Markt eingeführt. Die neuen Kits zur Erstellung genetischer ...
(Date:6/16/2015)... 16, 2015 /CNW Telbec/ - handyem Inc. and ... the incorporation of handyem,s HPC-150 portable flow cytometer ... Mo-POD™. This unprecedented model of mobile laboratory platform ... the Pennsylvania Convention Center, ... th to 18 th 2015.  By ...
Breaking Biology News(10 mins):Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 2QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 3QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 4QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 5QIAGEN bringt in den USA neue Kits für die forensische DNA-Analyse auf den Markt 6handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3
... of the environmental pollutant perfluorooctanoic acid (PFOA) that mothers had ... in their daughters at 20 years of age. The findings ... the Norwegian Institute of Public Health participated. In recent ... of overweight children and adults worldwide. It is suspected that ...
... study led by the University of Melbourne has shown that ... ants in rival nests, and use the information to identify ... other instantly by their unique colours. The ant colony ... by priming all nest mates with information about rivals before ...
... in two new European projects focusing on type 2 ... choices and strategies for preventing the disease. Focus is ... the effects of changes in lifestyle. The goal includes ... of diabetes and exploiting the results in a major ...
Cached Biology News:Environmental pollutant linked with overweight 2Ant colonies remember rivals' odor and compete like sports fans 2VTT searches for novel biomarkers and targets for preventing or treating Type 2 diabetes 2
ANTI MYCOBACTERIUM TUBERCULOSIS...
IMAGEQUANT 100 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
IMAGEQUANT 300 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
Recombinant Feline IL-12/IL-23 p40 (C-Terminus), CF...
Biology Products: